Jubilant Pharmova Limited — Board Meeting, 16-05-2025: Outcome of Board Meeting

Jubilant Pharmova has announced a board meeting to approve the financial results for the quarter and half-year. Consolidated net profit surged to ₹836 Cr from ₹72.7 Cr last year, driven by strong revenue growth to ₹7,234.5 Cr. Radiopharma, Allergy Immunotherapy, and Sterile Injectables showed solid momentum, though Generics remained in the red. The company completed the acquisition of JASMIN in France, boosting its R&D capabilities. A final dividend of ₹5 per share has been proposed, pending shareholder approval.